R.G.C.C. : Research Genetic Cancer Center

rgcc Dr. med. Siebenhüner In our clinic, we use the well-known R.G.C.C.-testmethod for testing. Using the R.G.C.C. blood-analysis is an excellent way to establish a personalized cancer-therapy. We collect blood in our clinic which is then sent to the R.G.C.C. laboratory, where the circulating tumor-cells and cancer stem-cells are tested. Based on the results of the analysis, we are able to design together with the patient an individual treatment-plan inn order to improve the efficiency of the treatments. With it’s specialized analysis for a personalized cancer-treatment, the R.G.C.C. has achieved worldwide great advancements of the survival-rate of cancer-patients. The R.G.C.C. test was developed in order to find out which kind of individual cancer-treatment is best for treating the patient. Using the most advanced and innovative technologies of molecular- and cellular-biology enables R.G.C.C. to overcome the problems that were until now associated with the analysis of circulating tumor cells and circulating stem-cells. The extensive amount of data and information that is gained by this method is especially valuable for the identification of new target-molecules that are relevant for the disease. And, they can also be used in the clinical practice for new and precise test-procedures, for example for the risk evaluation or classification of cancer-patients. The R.G.C.C. laboratory test can be used for testing in conjunction with conventional as well as alternative treatment methods. The following items can be tested in the R.G.C.C. laboratory:


1. Chemo-agents:

Cisplatin, Carbonplatin, Cyclophosphamid, Ifosphamie, Dacarbazin, Oxaliplatin, Mitomycin, Melphalan, Treosulfan, Temozolomid, Procarbazin, BCNU, ACNU, CCNU, Bleomycin, Trophosphamid, Estramustin, Bendamustin, Doxorubicin, Liposomal, Doxorubicin, Epirubicin, Daunorbicin, Dactonomycin, Ironetecan, Topotecan, Idarubicin, Paclitaxel, Docetaxel, Vinblastie, Vinorelbin, %FU, Methatrexat, Gemcitabine, Capecitabine, Etoposide, Mitaxantrone, Floxuridine, Uracil-Tegafur, Ralitrexed, Pemetrexed.

2. Targeted substances

(with permanently increasing tendency) including monoclonal antobodies and low-molecular inhibitors: Cetuximab, Rituximab, Transtuzumab, Imatinib, Mesylat, Coxibs, Monteleucast, Tamoxifen, Raloxifen, Leprolid, Anastrozol, Bevacizumab, Suramin sulphate, mTOR-linhibitoren, Sorafenib und Sunitinib,Bortezomib sowie Thalidomid (antiangiogenetisch, Apoptose einleitend) Prüfung der Signalwege bzgl. Mutations-Downstream.

3. Immune-modificators:

IL-2, IFN, Cortisol

4. Bio- modificators:

Inhibitors of resistency-mechanisms: Disulfiram, Verapamil, Ketaconazol, 5-Azacytidin. A genetic profile of the CTC (circulating tumor cell) will be developed together with additional possible targets, as for example: NFkβ, as well as the status of hormone-receptors and heat-shock proteins Proteine (HSP 27, HSP 90 and HSP 72).

5. Natural Substances / Nutritional supplements

High-dosage vitamin C, Poly MVA, Carnivora, Quercetin, Indol 3 Carbinol, Mistletoe, C Statin, Ukrain, H2O2, Co Enzyme Q10, Essiac Tea, modified citrus pectin, IP6, Pancreatic Enzyme, Salvestrole, Uncaria Tomentosa, Cawsiumchloride, Carctol, Noni Juice, Annonaceae Acetogenine, Reolysin, B17, Maitake, Curcumin, Lycopene, Greentea Extract, Artsunate, Melatonin, Ellagic acid, L-Methionine, N-acetyl Cysteine, Niacin, L-Carnitin, Vitamine E, Superoxid- Dismutase, Aloe Vera, Selenium, IFNa2, Propolis, CV247, Avemar Powder.